Invesco
AUTL

Invesco’s Autolus Therapeutics AUTL Stock Holding History

Invesco’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.4K Buy
53,153
+1,511
+3% +$2.29K ﹤0.01% 3659
2025
Q4 		$103K Buy
51,642
+13,593
+36% +$20.9K ﹤0.01% 3635
2025
Q3 		$62K Buy
38,049
+8,413
+28% +$16.4K ﹤0.01% 3732
2025
Q2 		$67.6K Sell
29,636
-3,102
-9% -$5.13K ﹤0.01% 3696
2025
Q1 		$50.7K Buy
32,738
+11,381
+53% +$23.1K ﹤0.01% 3697
2024
Q4 		$50.2K Buy
21,357
+2,609
+14% +$8.82K ﹤0.01% 3688
2024
Q3 		$68.1K Buy
18,748
+2,424
+15% +$9.67K ﹤0.01% 3655
2024
Q2 		$56.8K Buy
16,324
+5,253
+47% +$22.7K ﹤0.01% 3810
2024
Q1 		$70.6K Buy
11,071
+993
+10% +$6.19K ﹤0.01% 3773
2023
Q4 		$64.9K Sell
10,078
-236
-2% -$900 ﹤0.01% 3733
2023
Q3 		$24K Sell
10,314
-385
-4% -$1.1K ﹤0.01% 3850
2023
Q2 		$25.5K Buy
+10,699
New +$25.4K ﹤0.01% 3852

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco's AUTL Position: Q1 2026 in Review

Invesco increased its Autolus Therapeutics (AUTL) stake by 2.9% in Q1 2026, buying an estimated $2.29K and bringing the position to 53,153 shares worth $73.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3659.

Invesco first reported a position in AUTL in Q2 2023 and has held it in 12 quarters since. The position peaked at $103K in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q1 2026.

  • Invesco held 53,153 shares of Autolus Therapeutics worth $73.4K as of Q1 2026.
  • Invesco bought 1,511 Autolus Therapeutics shares in Q1 2026, an estimated $2.29K.
  • Autolus Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3659 holding.
  • Invesco first reported a position in Autolus Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Invesco's Autolus Therapeutics position peaked at $103K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.